142 related articles for article (PubMed ID: 22320867)
1. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer.
Magkou C; Giannopoulou I; Theohari I; Fytou A; Rafailidis P; Nomikos A; Papadimitriou C; Nakopoulou L
Histopathology; 2012 Jun; 60(7):1125-32. PubMed ID: 22320867
[TBL] [Abstract][Full Text] [Related]
2. Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: is there any difference between premenopausal and postmenopausal women?
Petricević J; Petković M; Jonjić N
Acta Clin Croat; 2011 Jun; 50(2):169-75. PubMed ID: 22263379
[TBL] [Abstract][Full Text] [Related]
3. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
4. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
[TBL] [Abstract][Full Text] [Related]
5. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
6. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical evaluation of phosphorylated Akt at threonine 308 [pAkt(Thr308)] in invasive breast cancer.
Magkou C; Mylona E; Theohari I; Giannopoulou I; Papanikolaou E; Markaki S; Nakopoulou L
In Vivo; 2007; 21(6):967-72. PubMed ID: 18210742
[TBL] [Abstract][Full Text] [Related]
8. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
Hartog H; Horlings HM; van der Vegt B; Kreike B; Ajouaou A; van de Vijver MJ; Marike Boezen H; de Bock GH; van der Graaf WT; Wesseling J
Breast Cancer Res Treat; 2011 Oct; 129(3):725-36. PubMed ID: 21107683
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma.
Takei H; Iino Y; Horiguchi J; Kanoh T; Takao Y; Oyama T; Morishita Y
Anticancer Res; 1995; 15(3):1101-5. PubMed ID: 7544088
[TBL] [Abstract][Full Text] [Related]
10. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta.
Papadaki I; Mylona E; Giannopoulou I; Markaki S; Keramopoulos A; Nakopoulou L
Histopathology; 2005 Jan; 46(1):37-42. PubMed ID: 15656884
[TBL] [Abstract][Full Text] [Related]
11. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma.
Zheng W; Zheng J; Ma L; Meng F; Huang L; Ma D
APMIS; 2005 Mar; 113(3):175-81. PubMed ID: 15799760
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
14. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.
Widschwendter A; Tonko-Geymayer S; Welte T; Daxenbichler G; Marth C; Doppler W
Clin Cancer Res; 2002 Oct; 8(10):3065-74. PubMed ID: 12374673
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
19. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
